Evaluation of Efficacy and Safety of Early in Hospital Initiation of Inclisiran Treatment in Patients With Acute Coronary Syndromes

PHASE3Not yet recruitingINTERVENTIONAL

Enrollment

300

Participants

Timeline

Start Date

September 30, 2025

Primary Completion Date

March 6, 2027

Study Completion Date

March 6, 2027

Conditions

Acute Coronary Syndrome

Interventions

DRUG

Placebo

The participants will receive placebo subcutaneous at randomization (Day 1, Baseline visit) and Day 90

DRUG

Inclisiran

The participants will receive Inclisiran sodium 300 mg subcutaneous at randomization (Day 1, Baseline visit) and Day 90